Nikhil Lalwani Ani Pharmaceuticals Inc (ANIP) insider trading activity

Nikhil Lalwani is PRESIDENT & CEO of ANI PHARMACEUTICALS INC. Currently has a direct ownership of 377,505 shares of ANIP, which is worth approximately $24 Million. The most recent transaction as insider was on May 14, 2024, when has been sold 16,669 shares (Common Stock) at a price of $66.1 per share, resulting in proceeds of $1,101,820. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 378K

4.23% 3M change

50.5% 12M change

Total Value Held $24 Million

Nikhil Lalwani Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
May 14 2024	SELL Open market or private sale	$1,101,820 $66.1 p/Share	16,669 Reduced 4.23%	377,505 Common Stock
Mar 23 2024	SELL Payment of exercise price or tax liability	$1,214,518 $69.58 p/Share	17,455 Reduced 4.24%	394,174 Common Stock
Mar 08 2024	SELL Open market or private sale	$1,093,681 $67.13 p/Share	16,292 Reduced 3.81%	411,629 Common Stock
Mar 07 2024	SELL Payment of exercise price or tax liability	$1,138,072 $66.71 p/Share	17,060 Reduced 3.83%	427,921 Common Stock
Mar 06 2024	SELL Open market or private sale	$1,897,786 $65.52 p/Share	28,965 Reduced 6.11%	444,981 Common Stock
Feb 29 2024	SELL Payment of exercise price or tax liability	$677,647 $67.67 p/Share	10,014 Reduced 2.07%	473,946 Common Stock
Feb 14 2024	BUY Grant, award, or other acquisition	-	134,216 Added 21.71%	483,960 Common Stock

Sep 08 2023	SELL Payment of exercise price or tax liability	$225,833 $61.94 p/Share	3,646 Reduced 1.03%	349,744 Common Stock
Aug 15 2023	SELL Open market or private sale	$710,086 $61.13 p/Share	11,616 Reduced 3.18%	353,390 Common Stock
Aug 15 2023	BUY Exercise of conversion of derivative security	$336,864 $29.0 p/Share	11,616 Added 3.08%	365,006 Common Stock
Aug 11 2023	SELL Open market or private sale	$3,272,461 $57.75 p/Share	56,666 Reduced 13.82%	353,390 Common Stock
Mar 23 2023	SELL Payment of exercise price or tax liability	$660,148 $37.82 p/Share	17,455 Reduced 6.51%	250,840 Common Stock
Mar 07 2023	SELL Payment of exercise price or tax liability	$604,270 $44.23 p/Share	13,662 Reduced 4.85%	268,295 Common Stock
Feb 28 2023	BUY Grant, award, or other acquisition	-	159,216 Added 27.97%	410,056 Common Stock
Sep 08 2022	SELL Payment of exercise price or tax liability	$137,126 $37.61 p/Share	3,646 Reduced 1.28%	281,957 Common Stock
Apr 27 2022	BUY Grant, award, or other acquisition	-	33,352 Added 10.46%	285,603 Common Stock
Mar 24 2022	BUY Grant, award, or other acquisition	-	100,055 Added 28.4%	252,251 Common Stock
Mar 23 2022	SELL Payment of exercise price or tax liability	$471,782 $27.03 p/Share	17,454 Reduced 10.29%	152,196 Common Stock
Mar 21 2022	BUY Open market or private purchase	$200,033 $27.69 p/Share	7,224 Added 4.08%	169,650 Common Stock
Sep 08 2021	SELL Payment of exercise price or tax liability	$72,671 $28.2 p/Share	2,577 Reduced 1.56%	162,426 Common Stock
Mar 23 2021	BUY Grant, award, or other acquisition	-	136,495 Added 45.27%	165,003 Common Stock

Nikhil Lalwani

PRESIDENT & CEO

Baudette, MN

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells ANIP shares.

Notify only if

Value

Insider Trading

Get notified when an Ani Pharmaceuticals Inc insider buys or sells ANIP shares.

Notify only if

Operation

Value

Type

News

Receive news related to ANI PHARMACEUTICALS INC

Track Activities on ANIP

Account